KR100586625B1 - 저-독성의 사람 인터페론-알파 유사체 - Google Patents

저-독성의 사람 인터페론-알파 유사체 Download PDF

Info

Publication number
KR100586625B1
KR100586625B1 KR1020007004158A KR20007004158A KR100586625B1 KR 100586625 B1 KR100586625 B1 KR 100586625B1 KR 1020007004158 A KR1020007004158 A KR 1020007004158A KR 20007004158 A KR20007004158 A KR 20007004158A KR 100586625 B1 KR100586625 B1 KR 100586625B1
Authority
KR
South Korea
Prior art keywords
leu
arg
amino acid
glu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007004158A
Other languages
English (en)
Korean (ko)
Other versions
KR20010031206A (ko
Inventor
존슨하워드엠.
폰저카롤에이취
빌라렛로렐리에이취.
캄포스잭커라인
Original Assignee
펩젠 코포레이션
유니버시티 오브 플로리다
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펩젠 코포레이션, 유니버시티 오브 플로리다 filed Critical 펩젠 코포레이션
Publication of KR20010031206A publication Critical patent/KR20010031206A/ko
Application granted granted Critical
Publication of KR100586625B1 publication Critical patent/KR100586625B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020007004158A 1997-10-20 1998-10-20 저-독성의 사람 인터페론-알파 유사체 Expired - Fee Related KR100586625B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8/954,395 1997-10-20
US08/954,395 US6204022B1 (en) 1996-04-12 1997-10-20 Low-toxicity human interferon-alpha analogs
US08/954,395 1997-10-20
PCT/US1998/021936 WO1999020653A1 (en) 1997-10-20 1998-10-20 Low-toxicity human interferon-alpha analog

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067002021A Division KR100861007B1 (ko) 1997-10-20 1998-10-20 저-독성의 사람 인터페론-알파 유사체

Publications (2)

Publication Number Publication Date
KR20010031206A KR20010031206A (ko) 2001-04-16
KR100586625B1 true KR100586625B1 (ko) 2006-06-07

Family

ID=25495373

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020007004158A Expired - Fee Related KR100586625B1 (ko) 1997-10-20 1998-10-20 저-독성의 사람 인터페론-알파 유사체
KR1020067002021A Expired - Fee Related KR100861007B1 (ko) 1997-10-20 1998-10-20 저-독성의 사람 인터페론-알파 유사체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067002021A Expired - Fee Related KR100861007B1 (ko) 1997-10-20 1998-10-20 저-독성의 사람 인터페론-알파 유사체

Country Status (13)

Country Link
US (1) US6204022B1 (https=)
EP (1) EP1025124B1 (https=)
JP (2) JP2001520238A (https=)
KR (2) KR100586625B1 (https=)
CN (1) CN1240717C (https=)
AT (1) ATE402957T1 (https=)
AU (1) AU744774B2 (https=)
CA (1) CA2308116C (https=)
DE (1) DE69839812D1 (https=)
DK (1) DK1025124T3 (https=)
ES (1) ES2310931T3 (https=)
TW (1) TW593336B (https=)
WO (1) WO1999020653A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
AU781377B2 (en) * 1999-08-27 2005-05-19 University Of Florida Research Foundation, Inc. Materials and methods for inhibition of IgE production
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
KR20040022244A (ko) 2001-08-12 2004-03-11 펩젠 코포레이션 하이브리드 인터페론/인터페론 타우 단백질, 조성물 및사용방법
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN102836420B (zh) * 2003-03-03 2014-03-12 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CA2612901A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
RU2288474C1 (ru) * 2005-12-28 2006-11-27 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) Способ определения токсического действия оральной мукозальной интерферонотерапии
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0146903A3 (en) 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
EP0240224A3 (en) 1986-03-31 1989-02-01 Interferon Sciences, Inc. An alpha interferon analogue
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW391983B (en) 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them

Also Published As

Publication number Publication date
DE69839812D1 (de) 2008-09-11
CA2308116A1 (en) 1999-04-29
EP1025124B1 (en) 2008-07-30
EP1025124A1 (en) 2000-08-09
JP2008247926A (ja) 2008-10-16
AU744774B2 (en) 2002-03-07
US6204022B1 (en) 2001-03-20
KR20060015701A (ko) 2006-02-17
ATE402957T1 (de) 2008-08-15
WO1999020653A1 (en) 1999-04-29
CN1276797A (zh) 2000-12-13
DK1025124T3 (da) 2008-10-06
KR100861007B1 (ko) 2008-09-30
TW593336B (en) 2004-06-21
KR20010031206A (ko) 2001-04-16
ES2310931T3 (es) 2009-01-16
JP2001520238A (ja) 2001-10-30
CN1240717C (zh) 2006-02-08
CA2308116C (en) 2010-12-14
AU9807298A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
KR100586625B1 (ko) 저-독성의 사람 인터페론-알파 유사체
US6174996B1 (en) Hybrid interferon τ/type I interferon polypeptides
EP0914435B1 (en) Hybrid interferon compositions and methods of use
KR100223255B1 (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
TW585911B (en) Ovine and bovine interferon TAU, compositions thereof and pharmaceutical uses thereof
JP2001520238A5 (https=)
WO2013017653A1 (en) Hcv immunotherapy
Stebbing et al. Preclinical assessment of biological properties of recombinant DNA derived human interferons
US6231850B1 (en) Canine interleukin 12
Garotta et al. Development of interferon-γ antagonists as an example of biotechnology application to approach new immunomodulators
WO2000006596A2 (en) INTERFERON-alpha HYBRIDS
KR100464531B1 (ko) 잡종인터페론조성물및그것을사용하는방법
EP0556395A1 (en) Novel cytokine
AU706762B2 (en) Interferon tau compositions and methods of use
Cantell Is natural human leukocyte interferon still needed?
Schellekens et al. Interferons: past, present and future
REVEL Department of Virology, The Weizmann Institute of Science, Rehovot, Israel
STEWART II HETEROGENEITIES OF HUMAN
HK1059034A (en) Interferon tau composition and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080218

Republication note text: Notice of Request for Correction

Gazette number: 1005866250000

Gazette reference publication date: 20060607

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20070718

Effective date: 20080430

Free format text: TRIAL NUMBER: 2007105000064; TRIAL DECISION FOR CORRECTION REQUESTED 20070718

Effective date: 20080430

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20080430

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 0586625

Appeal request date: 20070718

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2007105000064

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090530

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090530